Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Healthy Adults
NCT04640402Phase 2Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Started Nov 2020; status: completed.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04640402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640402.